TiGenix: TiGenix participates in key conferences in the first half of 2015

Posted: February 2, 2015 at 5:51 am

PRESS RELEASE

TiGenix participates in key conferences in the first half of 2015

Leuven (BELGIUM) - 30 January, 2015 - TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today the conferences in which it is participating during the first half of 2015.

12-14 January Biotech Showcase 2015, San Francisco, USA Presenter: Eduardo Bravo, Chief Executive Officer

26-28 January Phacilitate Cell and Gene Therapy Conference, Washington, USA Presenter: Wilfried Dalemans, Chief Technical Officer

3 February Biotech and Money London 2015, London, UK Presenter: Eduardo Bravo, Chief Executive Officer

9-10 February Bio CEO and Investor Conference, New York, USA Presenter: Eduardo Bravo, Chief Executive Officer

18-21 February ECCO Inflammatory Bowel Diseases Congress, Barcelona, Spain Participants: Marie-Paule Richard, Chief Medical Officer; Maria Pascual, Vice President Regulatory Affairs and Corporate Quality; Mary Carmen Diez, Vice President Medical Affairs and New Product Commercialisation

9-11 March Bio Europe Spring 2015, Paris, France Participant: Claudia Jimenez, Senior Director Business Development

11 March Petercam Belgium Investor Day, Milan, Italy Participant: Claudia D'Augusta, Chief Financial Officer

Read the original:
TiGenix: TiGenix participates in key conferences in the first half of 2015

Related Posts